key: cord-0829932-ynkrhwrw
authors: Poulose, Vijo
title: Residual Lung Defects Among Survivors of Severe COVID-19 Infection
date: 2022-02-04
journal: Chest
DOI: 10.1016/j.chest.2021.09.034
sha: 29b9d255a35cd4f2ae72762e36c989275fa881fb
doc_id: 829932
cord_uid: ynkrhwrw

nan

range of physiologic states that are encountered in acutely ill patients.

We share your optimism with respect to an expanded role for ultrasound scanning as technology advances. With medical culture appropriately focused on patient safety, noninvasive diagnostic and monitoring tools will assume ever-increasing importance. Here ultrasound scanning, bolstered by robust study and improving technology, is positioned ideally to help improve patient outcome.

Despite our shared optimism, it is always important to emphasize the fact that ultrasound scanning, even at its best, remains but one piece of a complex clinical puzzle. Even if all ultrasonographic indexes pointed to a fluid responsive state, for example, the potential benefits of volume expansion must still be weighed against the known potential harms. 

To the Editor:

I read with great interest the study by Gonzalez et al 1 in the July 2021 issue of the CHEST in which they reported the 3-month health status (symptoms, pulmonary function, and radiologic features) of survivors who had been critically ill with COVID infection and who were admitted to the ICU. The results of such a study are of crucial importance to pulmonary physicians as we continue to battle the pandemic.

The investigators demonstrated that in the survivors, 82% had reduced diffusion capacity of carbon monoxide and up to 80% had radiologic anomalies. However, of the 125 recruited patients, only 62 (50%) were available for the 3-month assessment. Hence, it is quite possible that the patients who completed the study were the "sicker" group and the rest did not show up because they were well. So, the reported high proportion of patients with lung abnormalities could be an exaggerated value. 

Pulmonary function and radiologic features in survivors of critical COVID-19

To the Editor:We appreciate the interest in our study 1 and are thankful for the point raised. The statement that, of 125 patients who were admitted to the ICU during the study, only 62 could be reached for follow up is not entirely correct. As depicted in the flowchart of the original article, 36 patients died during the ICU stay; 10 patients were transferred to another hospital; three patients were under palliative treatment or were severely disabled, and one patient underwent follow up in another center. Thus, 75 patients were eligible for follow up at 3 months and consequently comprised the final cohort. Thirteen of them did not complete the pulmonary evaluation, given that seven patients were unreachable and only six patients (8% of the sample) declined to attend. The reasons for not attending the consultation are multiple. Although one could assume that the 8% of patients who declined to attend were healthy and recovered their daily lives, this number still represents a small proportion of patients to influence the main findings of the study and its final message.